| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |